Mycobacterium bovis BCG priming induces a strong potentiation of the antibody response induced by recombinant BCG expressing a foreign antigen.
Several recent studies have demonstrated that strong cellular or humoral immune responses can be induced against foreign antigens expressed by recombinant Mycobacterium bovis BCG. It has therefore been suggested that BCG could represent one of the best candidate vectors for live recombinant vaccines. However, a large percentage of the human population has been immunized by BCG, and this priming could modify the immune response to future recombinant BCG vaccines. In the present study, we have therefore compared the immune responses induced in naive and BCG-primed mice by two recombinant BCG vaccines expressing either beta-galactosidase or human immunodeficiency virus type 1 Nef antigens. Our results demonstrated that BCG priming limits the growth of recombinant BCG in mouse spleen or lymph nodes. This reduction in BCG growth was associated with decreased proliferative responses against Nef or beta-galactosidase antigens. This suppression, however, never exceeded 50%. Interestingly, in contrast to these reduced T-cell responses, BCG-primed mice developed high levels of anti-beta-galactosidase antibodies after immunization with recombinant BCG expressing this antigen. This stimulation of antibody responses was not due to polyclonal stimulation or to a nonspecific adjuvant effect of BCG. The isotypic patterns of anti-beta-galactosidase antibody responses induced by the recombinant BCG were similar in naive and BCG-primed mice. These results indicate that priming with BCG will not be a limitation for the use of recombinant BCG vaccines in humans.
Gheorghiu
M
M
Laboratoire du BCG, Institut Pasteur, Paris, France.
Lagranderie
M R
MR
Gicquel
B M
BM
Leclerc
C D
CD
D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis*; D001500:BCG Vaccine / Q000276:immunology*; D015693:Gene Products, nef / Q000276:immunology; D007114:Immunization; D007132:Immunoglobulin Isotypes / Q000032:analysis; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D014614:Vaccines, Synthetic / Q000276:immunology*; D001616:beta-Galactosidase / Q000276:immunology
D000907:Antibodies, Bacterial; D001500:BCG Vaccine; D015693:Gene Products, nef; D007132:Immunoglobulin Isotypes; D014614:Vaccines, Synthetic; D001616:beta-Galactosidase